Therefore, acting on the FXR might be a potential method to improve insulin and glucose sensitivity in diabetes mellitus (DM) and non-alcoholic fatty liver disease (NAFLD) [2,6]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.